A Phase 2 interventional study of Yiqilishui formula and Placebo in Sepsis Induced Myocardial Dysfunction, sponsored by Dongzhimen Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Dongzhimen Hospital, Beijing · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.
Among the 286 studies in Sepsis with a site in China, this one is the 70th largest by planned enrollment of the 121 interventional ones that give a count, is one of 26 that started in 2024, is one of 12 in phase 2, reaches primary completion later than 50 of the 105 other live ones, and was the 215th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:
Nanjing University · Sites in China
Ages 18+ · Healthy volunteers
Sir Run Run Shaw Hospital · Sites in China
Ages 18+ · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Southeast University, China · Sites in China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 19 · Phase 3 15 · Phase 4 17
First in 2004; this study’s year is marked. 26 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 118 across the 121 interventional studies, 180 across the 164 observational. Of the 87 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 286 have an industry lead sponsor. The 10 most frequent:
Dongzhimen Hospital, Beijing is the lead sponsor of 45 studies on the registry; 19 are open to participants now.
Dongzhimen Hospital, Beijing has 3 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
26 of the studies in Sepsis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07089186Phase 3Qilu Pharmaceutical Co., Ltd.Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections | 2026-12 |
| NCT05623722Jing Cai, MDErector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury | 2026-11-30 |
| NCT07367113Ying WangPeripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients | 2026-12 |
| NCT07413094Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | 2026-12 |
| NCT07950943Nanjing UniversityAI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor Decisions | 2026-12-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 286 studies in Sepsis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if Chinese medicine - Yiqilishui formula works to treat sepsis-induced myocardial dysfunction (SIMD). It will also learn about the safety of Yiqilishui formula. The main questions it aims to answer are:
Participants will:
Sepsis-induced myocardial dysfunction (SIMD) is characterized by high morbidity and mortality rates and remains a challenging issue in the field of critical care that has not yet been resolved. The main pathogenesis involves deficiency of Qi with water overflow and blood stasis and toxin blocking the channels. The use of a Qi-invigorating and diuretic formula has the effect of invigorating Qi, promoting diuresis, and detoxifying and unblocking the channels. This study employed a two-center prospective parallel randomized double-blind controlled trial, selecting a total of 80 SIMD subjects from the ICU of Tongzhou District Traditional Chinese Medicine Hospital and the ICU of Dongzhimen Hospital of Beijing University of Chinese Medicine, who met the inclusion and exclusion criteria. The subjects were randomly and evenly divided into a treatment group and a control group. Both groups received basic SIMD treatment, with the treatment group additionally receiving the oral or nasogastric administration of a granule preparation of Yiqilishui formula, and the control group receiving a placebo orally or nasogastrically. The intervention period was 7 days, with a follow-up period of 28 days. The primary efficacy indicators compared between the two groups were BNP and NT-proBNP, and the secondary efficacy indicators were echocardiography, myocardial injury markers, inflammatory markers, critical illness severity scores, ICU length of stay and costs, and 28-day survival rate. The study aimed to evaluate the clinical efficacy and safety of the Yiqilishui formula for SIMD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conventional Western medicine treatment + oral or nasogastric administration of Yiqilishui formula granules, twice daily;
Drug: Yiqilishui formula
Conventional Western medicine treatment + oral or nasal feeding of Yiqilishui formula placebo , twice daily.
Other: Placebo
Astragalus Root 30g, Angelica sinensis 30g, Honeysuckle Flower 30g, Capillary Artemisia Herb 15g, Giant Knotweed Rhizome 15g, Lepidium Seed 30g, Sichuan Lovage Rhizome 15g, Salvia Root 15g, Jujube Fruit 15g;
5% Yiqilishui Granules + 95% Dextrin;
BNP(B-type natriuretic peptide) decline rate
Blood samples were taken from the median cubital vein of the subjects at enrollment, on the 3rd day, the 7th day, and the 14th day to measure the BNP levels in the subjects' venous blood, calculate the patient's BNP decline rate, assess the severity of heart failure in the subjects, and predict their prognosis.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
The levels of cTnI
Cardiac injury markers-Blood samples from the median cubital vein of the subjects were taken at enrollment, on the 3rd day, the 7th day, and the 14th day to detect the levels of cardiac troponin I (cTnI)
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
The levels of CK-MB
Cardiac injury markers-Blood samples from the median cubital vein of the subjects were taken at enrollment, on the 3rd day, the 7th day, and the 14th day to detect the levels of creatine kinase MB isoenzyme
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
Concentration of H-FABP
Cardiac injury markers-Blood samples from the median cubital vein of the subjects were taken at enrollment, on the 3rd day, the 7th day, and the 14th day to detect the levels of heart-type fatty acid-binding protein
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
Tei index
At the time of subject enrollment, on the 3rd day, 7th day, and 14th day, Tei index were measured using transthoracic echocardiography to evaluate the subjects' cardiac function and structure.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
MEE
At the time of subject enrollment, on the 3rd day, 7th day, and 14th day, myocardial energy expenditure
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
LVMI
At the time of subject enrollment, on the 3rd day, 7th day, and 14th day, left ventricular mass index (LVMI) were measured using transthoracic echocardiography to evaluate the subjects' cardiac function and structure.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
The levels of WBC
Blood is drawn from the median cubital vein of the subjects at enrollment, on the 3rd day, the 7th day, and the 14th day. The levels of white blood cells (WBC) in the subjects' venous blood is detected.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
The percentage of NE%
Blood is drawn from the median cubital vein of the subjects at enrollment, on the 3rd day, the 7th day, and the 14th day. The percentage of neutrophils (NE%) in the subjects' venous blood is detected.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
The levels of CRP
Blood is drawn from the median cubital vein of the subjects at enrollment, on the 3rd day, the 7th day, and the 14th day. The levels of C-reactive protein (CRP) in the subjects' venous blood is detected.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
The levels of PCT
Blood is drawn from the median cubital vein of the subjects at enrollment, on the 3rd day, the 7th day, and the 14th day. The levels of procalcitonin (PCT) in the subjects' venous blood is detected.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
Concentration of IL-6
The supernatant serum is obtained by centrifugation, and the levels of interleukin-6 (IL-6) is measured by ELISA.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
Concentration of TNF-α
The supernatant serum is obtained by centrifugation, and the levels of tumor necrosis factor-α (TNF-α) is measured by ELISA.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
Concentration of ROS
The supernatant serum is obtained by centrifugation, and reactive oxygen species (ROS)is measured by ELISA.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
Concentration of ATP
The supernatant serum is obtained by centrifugation, and the levels of ATP content in the subjects' serum is measured by ELISA.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
Platelet aggregation rate
At enrollment, D3, D7, and D14, venous blood from patients is collected, platelet-rich plasma is prepared using differential centrifugation, and the platelet aggregation rate is determined by optical turbidimetry.
Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day
SOFA score
Sequential Organ Failure Assessment (SOFA score) is performed at the time of enrollment, on the 7th day, and on the 14th day. The SOFA score includes six systems: respiratory, circulation, liver, coagulation, kidney and central nervous system. Each system is scored according to different variables, with a score of 0 to 4 points, and a total score of 0 to 24 points. The higher the score, the worse the outcome.
Time frame: At enrollment, the 7th day, and the 14th day
Apache II score
Acute Physiology and Chronic Health Evaluation (Apache II score) is performed at the time of enrollment, on the 7th day, and on the 14th day. The Apache II score is scored from 0 to 71, and the higher the score, the worse the outcome.
Time frame: At enrollment, the 7th day, and the 14th day
ICU length of stay;
ICU length of stay,up to 100 weeks.
Time frame: From the date the participant is transferred to the ICU to the date he or she is finally transferred out of the ICU, assessed up to 100 weeks.
Outcome indicator
28-day mortality rate
Time frame: 28th day
The level of body temperature
During the intervention period, record the patient's underarm temperature measurement daily.
Time frame: Daily from enrollment to the 7th day.
Breathing rate
During the intervention period, record the patient's breathing rate measurement daily.
Time frame: Daily from enrollment to the 7th day.
Heart rate
During the intervention period, record the patient's heart rate measurement daily.
Time frame: Daily from enrollment to the 7th day.
The levels of blood pressure
During the intervention period, record the patient's blood pressure measurement daily.
Time frame: Daily from enrollment to the 7th day.
The levels of ALT
Before and after intervention period, record the patient's the levels of ALT.
Time frame: At enrollment and on the 7th day.
The levels of AST
Before and after intervention period, record the patient's the levels of AST.
Time frame: At enrollment and on the 7th day.
The levels of BUN
Before and after intervention period, record the patient's the levels of BUN.
Time frame: At enrollment and on the 7th day.
The levels of Cr
Before and after intervention period, record the patient's the levels of Cr.
Time frame: At enrollment and on the 7th day.
The levels of PT
Before and after intervention period, record the patient's the levels of Prothrombin Time(PT).
Time frame: At enrollment and on the 7th day.
The levels of APTT
Before and after intervention period, record the patient's the levels of Activated Partial Thromboplastin Time(APTT).
Time frame: At enrollment and on the 7th day.
The levels of INR
Before and after intervention period, record the patient's the levels of international normalized ratio(INR).
Time frame: At enrollment and on the 7th day.
The levels of TT
Before and after intervention period, record the patient's the levels of Thrombin Time(TT).
Time frame: At enrollment and on the 7th day.
The levels of D-D
Before and after intervention period, record the patient's the levels of D-dimer(D-D).
Time frame: At enrollment and on the 7th day.
The levels of FDP
Before and after intervention period, record the patient's the levels of Fibrin degradation products(FDP).
Time frame: At enrollment and on the 7th day.
Unexpected adverse reactions
Unexpected adverse reactions occurred during the intervention period.
Time frame: From enrollment to the 7th day, unexpected adverse reactions should be recorded at any time during the intervention period.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.
Of 43 non-industry phase 2 interventional studies under Sepsis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 35. This study's planned 25 months is below that.
Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dongzhimen Hospital, Beijing